Journal
MAYO CLINIC PROCEEDINGS
Volume 89, Issue 7, Pages 926-933Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.mayocp.2014.04.003
Keywords
-
Categories
Funding
- National Institutes of Health/National Cancer Institute [R01CA125614, R01CA168719]
- Al and Mary Agnes McQuinn
- Harold W. Siebens Foundation
- Richard M. Schulze Family Foundation
- National Cancer Institute RAID (Rapid Access to Intervention Development) Program
Ask authors/readers for more resources
MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 10(11) TCID50 (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites. Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Toxicities resolved within the first week after therapy. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated cancer. (C) 2014 Mayo Foundation for Medical Education and Research
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
